Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

The Challenge of Classifying Metastatic Cell Properties by Molecular Profiling Exemplified with Cutaneous Melanoma Cells and Their Cerebral Metastasis from Patient Derived Mouse Xenografts.

Neuditschko B, Janker L, Niederstaetter L, Brunmair J, Krivanek K, Izraely S, Sagi-Assif O, Meshel T, Keppler BK, Del Favero G, Witz IP, Gerner C.

Mol Cell Proteomics. 2020 Mar;19(3):478-489. doi: 10.1074/mcp.RA119.001886. Epub 2019 Dec 31.

2.

Regeneration Enhances Metastasis: A Novel Role for Neurovascular Signaling in Promoting Melanoma Brain Metastasis.

Prakash R, Izraely S, Thareja NS, Lee RH, Rappaport M, Kawaguchi R, Sagi-Assif O, Ben-Menachem S, Meshel T, Machnicki M, Ohe S, Hoon DS, Coppola G, Witz IP, Carmichael ST.

Front Neurosci. 2019 Apr 9;13:297. doi: 10.3389/fnins.2019.00297. eCollection 2019.

3.

The metastatic microenvironment: Melanoma-microglia cross-talk promotes the malignant phenotype of melanoma cells.

Izraely S, Ben-Menachem S, Sagi-Assif O, Telerman A, Zubrilov I, Ashkenazi O, Meshel T, Maman S, Orozco JIJ, Salomon MP, Marzese DM, Pasmanik-Chor M, Pikarski E, Ehrlich M, Hoon DSB, Witz IP.

Int J Cancer. 2019 Feb 15;144(4):802-817. doi: 10.1002/ijc.31745. Epub 2018 Nov 1.

4.

Cystatin C takes part in melanoma-microglia cross-talk: possible implications for brain metastasis.

Moshe A, Izraely S, Sagi-Assif O, Prakash R, Telerman A, Meshel T, Carmichael T, Witz IP.

Clin Exp Metastasis. 2018 Aug;35(5-6):369-378. doi: 10.1007/s10585-018-9891-0. Epub 2018 May 2.

5.

A history of exploring cancer in context.

Maman S, Witz IP.

Nat Rev Cancer. 2018 Jun;18(6):359-376. doi: 10.1038/s41568-018-0006-7. Review.

PMID:
29700396
6.

ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis.

Izraely S, Ben-Menachem S, Sagi-Assif O, Meshel T, Marzese DM, Ohe S, Zubrilov I, Pasmanik-Chor M, Hoon DSB, Witz IP.

Oncotarget. 2017 Jul 5;8(44):75778-75796. doi: 10.18632/oncotarget.19018. eCollection 2017 Sep 29.

7.

P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway.

Wang J, Hirose H, Du G, Chong K, Kiyohara E, Witz IP, Hoon DSB.

Cancer Lett. 2017 Oct 28;407:66-75. doi: 10.1016/j.canlet.2017.08.001. Epub 2017 Aug 10.

PMID:
28803992
8.

CCR4 is a determinant of melanoma brain metastasis.

Klein A, Sagi-Assif O, Meshel T, Telerman A, Izraely S, Ben-Menachem S, Bayry J, Marzese DM, Ohe S, Hoon DSB, Erez N, Witz IP.

Oncotarget. 2017 May 9;8(19):31079-31091. doi: 10.18632/oncotarget.16076.

9.

The Beta Subunit of Hemoglobin (HBB2/HBB) Suppresses Neuroblastoma Growth and Metastasis.

Maman S, Sagi-Assif O, Yuan W, Ginat R, Meshel T, Zubrilov I, Keisari Y, Lu W, Lu W, Witz IP.

Cancer Res. 2017 Jan 1;77(1):14-26. doi: 10.1158/0008-5472.CAN-15-2929. Epub 2016 Oct 28.

10.

Hexokinase 2 is a determinant of neuroblastoma metastasis.

Botzer LE, Maman S, Sagi-Assif O, Meshel T, Nevo I, Yron I, Witz IP.

Br J Cancer. 2016 Mar 29;114(7):759-66. doi: 10.1038/bjc.2016.26. Epub 2016 Mar 17.

11.

PHOX2B is a suppressor of neuroblastoma metastasis.

Naftali O, Maman S, Meshel T, Sagi-Assif O, Ginat R, Witz IP.

Oncotarget. 2016 Mar 1;7(9):10627-37. doi: 10.18632/oncotarget.7056.

12.

Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives.

Marzese DM, Witz IP, Kelly DF, Hoon DS.

Epigenomics. 2015;7(8):1303-11. doi: 10.2217/epi.15.77. Epub 2015 Dec 7. Review.

PMID:
26638944
13.

The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching.

Lessard L, Liu M, Marzese DM, Wang H, Chong K, Kawas N, Donovan NC, Kiyohara E, Hsu S, Nelson N, Izraely S, Sagi-Assif O, Witz IP, Ma XJ, Luo Y, Hoon DSB.

J Invest Dermatol. 2015 Oct;135(10):2464-2474. doi: 10.1038/jid.2015.200. Epub 2015 May 27.

14.

Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells.

Zubrilov I, Sagi-Assif O, Izraely S, Meshel T, Ben-Menahem S, Ginat R, Pasmanik-Chor M, Nahmias C, Couraud PO, Hoon DS, Witz IP.

Cancer Lett. 2015 May 28;361(1):86-96. doi: 10.1016/j.canlet.2015.02.041. Epub 2015 Feb 25.

PMID:
25725450
15.

Astrocytes facilitate melanoma brain metastasis via secretion of IL-23.

Klein A, Schwartz H, Sagi-Assif O, Meshel T, Izraely S, Ben Menachem S, Bengaiev R, Ben-Shmuel A, Nahmias C, Couraud PO, Witz IP, Erez N.

J Pathol. 2015 May;236(1):116-27. doi: 10.1002/path.4509. Epub 2015 Feb 12.

PMID:
25639230
16.

Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas.

Wang J, Huang SK, Marzese DM, Hsu SC, Kawas NP, Chong KK, Long GV, Menzies AM, Scolyer RA, Izraely S, Sagi-Assif O, Witz IP, Hoon DSB.

J Invest Dermatol. 2015 Feb;135(2):532-541. doi: 10.1038/jid.2014.418. Epub 2014 Sep 22.

17.

The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis.

Izraely S, Sagi-Assif O, Klein A, Meshel T, Ben-Menachem S, Zaritsky A, Ehrlich M, Prieto VG, Bar-Eli M, Pirker C, Berger W, Nahmias C, Couraud PO, Hoon DS, Witz IP.

Int J Cancer. 2015 Mar 15;136(6):1296-307. doi: 10.1002/ijc.29090. Epub 2014 Sep 8.

18.

The role played by the microenvironment in site-specific metastasis.

Klein-Goldberg A, Maman S, Witz IP.

Cancer Lett. 2014 Sep 28;352(1):54-8. doi: 10.1016/j.canlet.2013.08.029. Epub 2013 Aug 27. Review.

PMID:
23988268
19.

The metastatic microenvironment: lung-derived factors control the viability of neuroblastoma lung metastasis.

Maman S, Edry-Botzer L, Sagi-Assif O, Meshel T, Yuan W, Lu W, Witz IP.

Int J Cancer. 2013 Nov 15;133(10):2296-306. doi: 10.1002/ijc.28255. Epub 2013 Jun 14.

20.

The metastatic microenvironment: Brain-derived soluble factors alter the malignant phenotype of cutaneous and brain-metastasizing melanoma cells.

Klein A, Sagi-Assif O, Izraely S, Meshel T, Pasmanik-Chor M, Nahmias C, Couraud PO, Erez N, Hoon DS, Witz IP.

Int J Cancer. 2012 Dec 1;131(11):2509-18. doi: 10.1002/ijc.27552. Epub 2012 Apr 12.

21.

The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis.

Izraely S, Sagi-Assif O, Klein A, Meshel T, Tsarfaty G, Pasmanik-Chor M, Nahmias C, Couraud PO, Ateh E, Bryant JL, Hoon DS, Witz IP.

Int J Cancer. 2012 Sep 1;131(5):1071-82. doi: 10.1002/ijc.27324. Epub 2011 Dec 2.

22.

Lung-residing metastatic and dormant neuroblastoma cells.

Edry Botzer L, Maman S, Sagi-Assif O, Meshel T, Nevo I, Bäuerle T, Yron I, Witz IP.

Am J Pathol. 2011 Jul;179(1):524-36. doi: 10.1016/j.ajpath.2011.03.020. Epub 2011 May 3.

23.

The 5th international conference on tumor microenvironment: progression, therapy and prevention versailles, france, october 20-24, 2009: conference summary.

Mohla S, Witz IP.

Cancer Microenviron. 2010 Feb 18;3(1):1-5. doi: 10.1007/s12307-010-0039-2. No abstract available.

24.

Introducing the cancer microenvironment section of Journal of Translational Medicine.

Vidal-Vanaclocha F, Witz IP.

J Transl Med. 2010 Jun 22;8:60. doi: 10.1186/1479-5876-8-60. No abstract available.

25.

Chemokine-chemokine receptor axes in melanoma brain metastasis.

Izraely S, Klein A, Sagi-Assif O, Meshel T, Tsarfaty G, Hoon DS, Witz IP.

Immunol Lett. 2010 May 4;130(1-2):107-14. doi: 10.1016/j.imlet.2009.12.003. Epub 2009 Dec 30.

PMID:
20005902
26.

Gene-expression-based analysis of local and metastatic neuroblastoma variants reveals a set of genes associated with tumor progression in neuroblastoma patients.

Nevo I, Oberthuer A, Botzer E, Sagi-Assif O, Maman S, Pasmanik-Chor M, Kariv N, Fischer M, Yron I, Witz IP.

Int J Cancer. 2010 Apr 1;126(7):1570-81. doi: 10.1002/ijc.24889.

27.

The tumor microenvironment: the making of a paradigm.

Witz IP.

Cancer Microenviron. 2009 Sep;2 Suppl 1:9-17. doi: 10.1007/s12307-009-0025-8. Epub 2009 Aug 23.

28.

The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells.

Nevo I, Sagi-Assif O, Meshel T, Ben-Baruch A, Jöhrer K, Greil R, Trejo LE, Kharenko O, Feinmesser M, Yron I, Witz IP.

Cancer Lett. 2009 Jan 8;273(1):127-39. doi: 10.1016/j.canlet.2008.07.029. Epub 2008 Sep 7.

PMID:
18778890
29.

Generation and characterization of novel local and metastatic human neuroblastoma variants.

Nevo I, Sagi-Assif O, Edry Botzer L, Amar D, Maman S, Kariv N, Leider-Trejo LE, Savelyeva L, Schwab M, Yron I, Witz IP.

Neoplasia. 2008 Aug;10(8):816-27.

30.

Tumor-microenvironment interactions: dangerous liaisons.

Witz IP.

Adv Cancer Res. 2008;100:203-29. doi: 10.1016/S0065-230X(08)00007-9. Review.

PMID:
18620097
31.

E-selectin regulates gene expression in metastatic colorectal carcinoma cells and enhances HMGB1 release.

Aychek T, Miller K, Sagi-Assif O, Levy-Nissenbaum O, Israeli-Amit M, Pasmanik-Chor M, Jacob-Hirsch J, Amariglio N, Rechavi G, Witz IP.

Int J Cancer. 2008 Oct 15;123(8):1741-50. doi: 10.1002/ijc.23375.

32.

The involvement of the sLe-a selectin ligand in the extravasation of human colorectal carcinoma cells.

Ben-David T, Sagi-Assif O, Meshel T, Lifshitz V, Yron I, Witz IP.

Immunol Lett. 2008 Mar 15;116(2):218-24. doi: 10.1016/j.imlet.2007.11.022. Epub 2007 Dec 26.

PMID:
18191232
33.

The selectin-selectin ligand axis in tumor progression.

Witz IP.

Cancer Metastasis Rev. 2008 Mar;27(1):19-30. doi: 10.1007/s10555-007-9101-z. Review.

PMID:
18180878
34.

Yin-yang activities and vicious cycles in the tumor microenvironment.

Witz IP.

Cancer Res. 2008 Jan 1;68(1):9-13. doi: 10.1158/0008-5472.CAN-07-2917. Review. No abstract available.

35.

CXCL10 promotes invasion-related properties in human colorectal carcinoma cells.

Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP, Ben-Baruch A.

Cancer Res. 2007 Apr 1;67(7):3396-405.

36.
37.

The tumor microenvironment in the post-PAGET era.

Witz IP, Levy-Nissenbaum O.

Cancer Lett. 2006 Oct 8;242(1):1-10. Epub 2006 Jan 18. Review.

PMID:
16413116
38.

The Pyst2-L phosphatase is involved in cell-crowding.

Levy-Nissenbaum O, Ben-Menachem S, Sagi-Assif O, Witz IP.

Immunol Lett. 2006 Apr 15;104(1-2):138-45. Epub 2005 Dec 9.

PMID:
16386315
39.

The involvement of selectins and their ligands in tumor-progression.

Witz IP.

Immunol Lett. 2006 Apr 15;104(1-2):89-93. Epub 2005 Dec 6. Review.

PMID:
16368149
40.

Cellular characteristics of neuroblastoma cells: regulation by the ELR--CXC chemokine CXCL10 and expression of a CXCR3-like receptor.

Goldberg-Bittman L, Sagi-Assif O, Meshel T, Nevo I, Levy-Nissenbaum O, Yron I, Witz IP, Ben-Baruch A.

Cytokine. 2005 Feb 7;29(3):105-17. Epub 2004 Dec 2.

PMID:
15613278
41.

Tumor-microenvironment interactions: the fucose-generating FX enzyme controls adhesive properties of colorectal cancer cells.

Zipin A, Israeli-Amit M, Meshel T, Sagi-Assif O, Yron I, Lifshitz V, Bacharach E, Smorodinsky NI, Many A, Czernilofsky PA, Morton DL, Witz IP.

Cancer Res. 2004 Sep 15;64(18):6571-8. Erratum in: Cancer Res. 2004 Nov 1;64(21):8130.

42.

The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines.

Goldberg-Bittman L, Neumark E, Sagi-Assif O, Azenshtein E, Meshel T, Witz IP, Ben-Baruch A.

Immunol Lett. 2004 Mar 29;92(1-2):171-8.

PMID:
15081542
43.

The tumor microenvironment: CXCR4 is associated with distinct protein expression patterns in neuroblastoma cells.

Nevo I, Sagi-Assif O, Meshel T, Geminder H, Goldberg-Bittman L, Ben-Menachem S, Shalmon B, Goldberg I, Ben-Baruch A, Witz IP.

Immunol Lett. 2004 Mar 29;92(1-2):163-9.

PMID:
15081541
44.

Does the dual-specificity MAPK phosphatase Pyst2-L lead a monogamous relationship with the Erk2 protein?

Orlev LN, Ehud B, Tamar BG, Orit SA, Yoel K, Witz IP.

Immunol Lett. 2004 Mar 29;92(1-2):149-56.

PMID:
15081539
45.

cDNA microarray analysis reveals an overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia.

Levy-Nissenbaum O, Sagi-Assif O, Raanani P, Avigdor A, Ben-Bassat I, Witz IP.

Methods Enzymol. 2003;366:103-13.

PMID:
14674243
46.

Characterization of the dual-specificity phosphatase PYST2 and its transcripts.

Levy-Nissenbaum O, Sagi-Assif O, Witz IP.

Genes Chromosomes Cancer. 2004 Jan;39(1):37-47. Erratum in: Genes Chromosomes Cancer. 2004 Feb;39(2):170.

PMID:
14603440
47.

Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells.

Levy-Nissenbaum O, Sagi-Assif O, Kapon D, Hantisteanu S, Burg T, Raanani P, Avigdor A, Ben-Bassat I, Witz IP.

Oncogene. 2003 Oct 23;22(48):7649-60.

PMID:
14576828
48.

Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia.

Levy-Nissenbaum O, Sagi-Assif O, Raanani P, Avigdor A, Ben-Bassat I, Witz IP.

Cancer Lett. 2003 Sep 25;199(2):185-92.

PMID:
12969791
49.

Progression of mouse mammary tumors: MCP-1-TNFalpha cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors.

Neumark E, Sagi-Assif O, Shalmon B, Ben-Baruch A, Witz IP.

Int J Cancer. 2003 Oct 10;106(6):879-86.

50.

The focal adhesion kinase (P125FAK) is constitutively active in human malignant melanoma.

Kahana O, Micksche M, Witz IP, Yron I.

Oncogene. 2002 Jun 6;21(25):3969-77.

Supplemental Content

Support Center